Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

ELIQUIS

×

Overview

What is ELIQUIS?

ELIQUIS (apixaban), a factor Xa (FXa) inhibitor, is chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1-pyrazolo[3,4-]pyridine-3-carboxamide. Its molecular formula is CHNO, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula:

Apixaban is a white to pale-yellow powder. At physiological pH (1.2-6.8), apixaban does not ionize; its aqueous solubility across the physiological pH range is ~0.04 mg/mL.

ELIQUIS tablets are available for oral administration in strengths of 2.5 mg and 5 mg of apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).



What does ELIQUIS look like?



What are the available doses of ELIQUIS?

What should I talk to my health care provider before I take ELIQUIS?

How should I use ELIQUIS?

ELIQUIS (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

•

•

•

•


What interacts with ELIQUIS?

Sorry No Records found


What are the warnings of ELIQUIS?

Sorry No Records found


What are the precautions of ELIQUIS?

Sorry No Records found


What are the side effects of ELIQUIS?

Sorry No records found


What should I look out for while using ELIQUIS?

ELIQUIS is contraindicated in patients with the following conditions:


What might happen if I take too much ELIQUIS?

There is no antidote to ELIQUIS. Overdose of ELIQUIS increases the risk of bleeding .

In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects.

In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.


How should I store and handle ELIQUIS?

Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807Atenolol and Chlorthalidone Tablets USP, 50 mg-25 mg are 10/32”, scored, round, white tablets imprinted  supplied inBottles of 30 - 68788-9042-3Bottles of 60 - 68788-9042-6Bottles of 90 - 68788-9042-9Bottles of 100 - 68788-9042-1Bottles of 120 - 68788-9042-8Dispense in a well-closed, light-resistant container with a child-resistant closure.Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]Protect from heat, light and moisture.Manufactured by: Verna, Salcette Goa 403 722 INDIADistributed by: Corona, CA 92880 USARevised: June 2009        1908080609BRepackaged by: Anaheim, CA 92807


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

Non-Clinical Toxicology
ELIQUIS is contraindicated in patients with the following conditions:

Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.

Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See)

Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrine. Thiazides may increase the responsiveness to tubocurarine.

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta blockers.

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Read prescribing information for lithium preparations before use of such preparations with atenolol and chlorthalidone.

Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.

While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.

Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant .

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).